Sökning: onr:"swepub:oai:lup.lub.lu.se:8a8a09e5-4031-457a-8d80-7ef33b70a93a" >
Pathogenic immunity...
-
Wigren, MariaLund University,Lunds universitet,Kardiovaskulär forskning - immunitet och ateroskleros,Forskargrupper vid Lunds universitet,Cardiovascular Research - Immunity and Atherosclerosis,Lund University Research Groups
(författare)
Pathogenic immunity in systemic lupus erythematous and atherosclerosis: common mechanisms and possible targets for intervention.
- Artikel/kapitelEngelska2015
Förlag, utgivningsår, omfång ...
-
2015-10-19
-
Wiley,2015
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:8a8a09e5-4031-457a-8d80-7ef33b70a93a
-
https://lup.lub.lu.se/record/5142633URI
-
https://doi.org/10.1111/joim.12357DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:for swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
Systemic lupus erythematous (SLE) is an autoimmune disorder that primarily affects young women and is characterized by inflammation in several organs including the kidneys, skin, joints, blood, and nervous system. Abnormal immune cellular and humoral responses play important roles in the development of the disease process. Impaired clearance of apoptotic material is a key factor contributing to activation of self-reactive immune cells. The incidence of atherosclerotic cardiovascular disease (CVD) is increased up to 50-fold in SLE patients compared to age- and gender-matched control subjects and this can only partly be explained by traditional risk factors for CVD. Currently, there is no effective treatment to prevent CVD complications in SLE. Traditional preventive CVD therapies have not been found to significantly lower the incidence of CVD in SLE; therefore, there is a need for novel treatment strategies and increased understanding of the mechanisms involved in the pathogenesis of CVD complications in SLE. The pathogenic immune responses in SLE and development of atherosclerotic plaques share some characteristics, such as impaired efferocytosis and skewed T cell activation, suggesting the possibility of identifying novel targets for intervention. As novel immune-based therapies for CVD are being developed, it is possible that some of these may be effective for the prevention of CVD and for immunomodulation in SLE. However, further understanding of the mechanisms leading to an increased prevalence of cardiovascular events in SLE is critical for the development of such therapies. This article is protected by copyright. All rights reserved.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Nilsson, JanLund University,Lunds universitet,Kardiovaskulär forskning - immunitet och ateroskleros,Forskargrupper vid Lunds universitet,Cardiovascular Research - Immunity and Atherosclerosis,Lund University Research Groups(Swepub:lu)medf-jni
(författare)
-
Kaplan, Mariana J
(författare)
-
Kardiovaskulär forskning - immunitet och aterosklerosForskargrupper vid Lunds universitet
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Journal of Internal Medicine: Wiley278:5, s. 494-5061365-27960954-6820
Internetlänk
Hitta via bibliotek
Till lärosätets databas